Abstract: Science Set Journal of Medical and Clinical Case Studies

Abstract:
Although immune checkpoint inhibitors (ICIs) significantly prolong the survival of patients with certain solid tumors by blocking specific signaling pathways, the immune-related adverse events (irAEs) they induce can affect multiple organs and even be life-threatening, restricting their clinical application. Studies have shown that patients who experience irAEs have improved progression-free survival (PFS) and overall survival (OS). Mechanistically, this may be related to the highly active state of the body's immune response. This "double-edged sword" characteristic of irAEs has prompted the academic community to re-examine its clinical significance, explore its use as a potential biomarker for evaluating therapeutic efficacy, and develop new adverse event management strategies to balance efficacy and safety.